Abstract
Bortezomib, a modified dipeptidyl boronic acid, is a selective potent proteasome inhibitor that has been approved for clinical treatment of multiple myeloma and mantel cell lymphoma. Results from a growing number of basic studies and clinical trials reveal that bortezomib could be used to treat diverse types of solid tumors alone or in combination with other chemotherapeutic drugs. It has been shown that bortezomib transcriptionally suppresses focal adhesion kinase (FAK) expression by interrupting the nuclear factor kappa B (NFκB) pathway, which suggests that FAK could be a potential molecular target for bortezomib. Analysis of FAK promoter sequences revealed that FAK promoter harbors the NFκB and p53 binding domains. Further studies of FAK promoter activity, real-time PCR, electrophoretic mobility shift assay (EMSA) and chromatin immunoprecipitation (ChIP) assay revealed that bortezomib inhibits NFκB binding on the FAK promoter, thereby reducing FAK expression. Thus, bortezomib could inhibit cancer cell growth and migration or invasion by repressing FAK expression. Since activation and overexpression of FAK has been implicated in the progression and invasion of malignant tumors, it is likely that targeting FAK with bortezomib is a potential strategy for preventing cancer metastasis. This review focuses on the molecular regulation of FAK and the potential clinical application of bortezomib.
Keywords: Bortezomib, Focal adhesion kinase, NFκB, p53, proteasome inhibitor, cancer treatment, Hepatocellular carcinoma, hematological malignancies, chromatin immunoprecipitation, EMSA, boronic acid, ubiquitin-proteasome, TRAIL, epoxomycin, actacystin
Anti-Cancer Agents in Medicinal Chemistry
Title: Focal Adhesion Kinase as a Therapeutic Target of Bortezomib
Volume: 10 Issue: 10
Author(s): Bor-Sheng Ko, Tzu-Ching Chang and Jun-Yang Liou
Affiliation:
Keywords: Bortezomib, Focal adhesion kinase, NFκB, p53, proteasome inhibitor, cancer treatment, Hepatocellular carcinoma, hematological malignancies, chromatin immunoprecipitation, EMSA, boronic acid, ubiquitin-proteasome, TRAIL, epoxomycin, actacystin
Abstract: Bortezomib, a modified dipeptidyl boronic acid, is a selective potent proteasome inhibitor that has been approved for clinical treatment of multiple myeloma and mantel cell lymphoma. Results from a growing number of basic studies and clinical trials reveal that bortezomib could be used to treat diverse types of solid tumors alone or in combination with other chemotherapeutic drugs. It has been shown that bortezomib transcriptionally suppresses focal adhesion kinase (FAK) expression by interrupting the nuclear factor kappa B (NFκB) pathway, which suggests that FAK could be a potential molecular target for bortezomib. Analysis of FAK promoter sequences revealed that FAK promoter harbors the NFκB and p53 binding domains. Further studies of FAK promoter activity, real-time PCR, electrophoretic mobility shift assay (EMSA) and chromatin immunoprecipitation (ChIP) assay revealed that bortezomib inhibits NFκB binding on the FAK promoter, thereby reducing FAK expression. Thus, bortezomib could inhibit cancer cell growth and migration or invasion by repressing FAK expression. Since activation and overexpression of FAK has been implicated in the progression and invasion of malignant tumors, it is likely that targeting FAK with bortezomib is a potential strategy for preventing cancer metastasis. This review focuses on the molecular regulation of FAK and the potential clinical application of bortezomib.
Export Options
About this article
Cite this article as:
Ko Bor-Sheng, Chang Tzu-Ching and Liou Jun-Yang, Focal Adhesion Kinase as a Therapeutic Target of Bortezomib, Anti-Cancer Agents in Medicinal Chemistry 2010; 10 (10) . https://dx.doi.org/10.2174/187152010794728666
DOI https://dx.doi.org/10.2174/187152010794728666 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Review of Recent Clinical Developments and Patents for the Treatment of Autoimmune and Inflammatory Diseases by Mesenchymal Stromal Cells
Recent Patents on Regenerative Medicine Application of Serial Analysis of Gene Expression in Cancer Research
Current Pharmaceutical Biotechnology Update on the Use of Biologics in Vasculitides
Current Pharmaceutical Biotechnology Therapeutic Targeting of CPT-11 Induced Diarrhea: A Case for Prophylaxis
Current Drug Targets Interaction of Mesalasine (5-ASA) with Translational Initiation Factors eIF4 Partially Explains 5-ASA Anti-Inflammatory and Anti-Neoplastic Activities
Medicinal Chemistry Immunotherapy of Acute Myeloid Leukemia
Current Pharmaceutical Biotechnology Current Perspective of Natural Alkaloid Carbazole and its Derivatives as Antitumor Agents
Anti-Cancer Agents in Medicinal Chemistry Editorial (Thematic Issue: Treatment of Cancer in the Elderly)
Anti-Cancer Agents in Medicinal Chemistry Current Gene Therapy Strategies for Colorectal Cancer
Current Genomics Plant Glycosides and Aglycones Displaying Antiproliferative and Antitumour Activities – A Review
Current Bioactive Compounds <i>Pulsatilla saponin</i> A Induces Apoptosis and Differentiation of Myeloma Cells
Anti-Cancer Agents in Medicinal Chemistry Regulation of Cell Death and Survival by Resveratrol: Implications for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Proteasome Inhibition as a New Therapeutic Principle in Hematological Malignancies
Current Drug Targets Onconase and Amphinase, the Antitumor Ribonucleases from Rana pipiens Oocytes
Current Pharmaceutical Biotechnology The Role of c-Myc in Beta Cell Mass Homeostasis
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Immune Checkpoint Inhibitors in AML-A New Frontier
Current Cancer Drug Targets Mouse Models of Myasthenia Gravis
Current Pharmaceutical Design Rexinoids for Prevention and Treatment of Cancer: Opportunities and Challenges
Current Topics in Medicinal Chemistry The High Mobility Group A1 (HMGA1) Transcriptome in Cancer and Development
Current Molecular Medicine Is There an Increased Risk of Lymphoma and Malignancies Under Anti- TNF Therapy in IBD?
Current Drug Targets